GM769_S6
IPSCZHi001-A
General
Cell Line |
|
| hPSCreg name | IPSCZHi001-A |
| Cite as: | IPSCZHi001-A (RRID:CVCL_D0G6) |
| Alternative name(s) |
GM769_S6
|
| Cell line type | Human induced pluripotent stem cell (hiPSC) |
| Similar lines | No similar lines found. |
| Last update | 19th June 2023 |
| User feedback | |
Provider |
|
| Generator |
iPSCore Zurich (IPSCZH)
Contact:
iPSCore Zurich (IPSCZH) |
| Owner | ETH Zurich |
| Derivation country | Switzerland |
External Databases |
|
| BioSamples | SAMEA113594962 |
| Cellosaurus | CVCL_D0G6 |
| Wikidata | Q123032739 |
General Information |
|
| * Is the cell line readily obtainable for third parties? |
No |
Donor Information
General Donor Information |
|
| Sex | female |
Phenotype and Disease related information (Donor) |
|
| Diseases | A disease was diagnosed.
|
External Databases (Donor) |
|
| BioSamples | SAMEA113611954 |
Ethics
| Has informed consent been obtained from the donor of the embryo/tissue from which the pluripotent stem cells have been derived? | Yes |
| Was the consent voluntarily given? | Yes |
| Has the donor been informed that participation will not directly influence their personal treatment? | Yes |
| Can you provide us with a copy of the Donor Information Sheet provided to the donor? | No |
| Provide contact information of the holder of the original Donor Information Sheet: | stephen.robertson@otago.ac.nz |
| Do you (Depositor/Provider) hold the original Donor Consent Form? | No |
| If you do not hold the Donor Consent Form, do you know who does? | No |
| Has the donor agreed to be re-contacted? | Unknown |
| Please indicate whether the data associated with the donated material has been pseudonymised or anonymised. | pseudonymised |
| Does consent explicitly allow the derivation of pluripotent stem cells? | Yes |
| Does consent prevent CELLS DERIVED FROM THE DONATED BIOSAMPLE from being made available to researchers anywhere in the world? | No |
| How may genetic information associated with the cell line be accessed? | Controlled Access |
| Will the donor expect to receive financial benefit, beyond reasonable expenses, in return for donating the biosample? | No |
| Has a favourable opinion been obtained from a research ethics committee, or other ethics review panel, in relation to the Research Protocol including the consent provisions? | Yes |
| Name of accrediting authority involved? | Health and Disability Ethics Committees Wellington |
| Approval number | 19/NTB/116 |
| Has a favourable opinion been obtained from a research ethics committee, or other ethics review panel, in relation to the PROPOSED PROJECT, involving use of donated embryo/tissue or derived cells? | Yes |
| Name of accrediting authority involved? | Ethik Kommission Nordwest und Zentralschweiz (EKNZ) |
| Approval number | 2020-02665 |
| For generation of the cell line, who was the supplier of any recombined DNA vectors or commercial kits used? |
hIPSC Derivation
General |
|
| Source cell type |
Synonyms
|
Reprogramming method |
|
| Vector type | Non-integrating |
| Vector | Sendai virus |
Vector free reprogramming |
|
Other |
|
| Derived under xeno-free conditions |
Unknown |
| Derived under GMP? |
Unknown |
| Available as clinical grade? |
Unknown |
Culture Conditions
| Surface coating | Vitronectin |
| Medium |
mTeSR™ 1
|
Characterisation
Analysis of Undifferentiated Cells
| Marker | Expressed | Immunostaining | RT-PCR | Flow Cytometry | Enzymatic Assay | Expression Profiles |
| SSEA-4 |
Yes |
|
||||
| TRA 1-60 |
Yes |
|
||||
| POU5F1 (OCT-4) |
Yes |
|
||||
| SOX2 |
Yes |
|
||||
| NANOG |
Yes |
|
||||
| ZFP42 (REX-1) |
Yes |
|
Differentiation Potency
Genotyping
Karyotyping (Cell Line) |
|
| Has the cell line karyotype been analysed? |
No
|
Other Genotyping (Cell Line) |
|
Login to share your feedback, experiences or results with the research community.